Dasatinib and Quercetin: The First Senolytic Combination Studied in Humans
Imagine a future where aging isn’t simply a relentless march forward, but a process you can temper or even partially reverse. While that may sound like science fiction, recent advances in the field of senolytics are bringing us closer to that reality. Among these, the combination of dasatinib and quercetin stands out as a pioneering duo—the first senolytic cocktail tested in humans. For anyone fascinated by longevity science or the quest to extend healthspan, understanding how these compounds work together offers a captivating glimpse into the evolving fight against age-related diseases.
Why Senolytics Matter for Longevity
Over time, our bodies accumulate senescent cells—damaged cells that have lost the ability to divide but stubbornly refuse to die. These “zombie cells” secrete inflammatory factors, disrupt tissue function, and contribute to the chronic diseases that often accompany aging, such as arthritis, diabetes, and cardiovascular disease. Senolytics are drugs designed to selectively eliminate these senescent cells, potentially alleviating their harmful effects.
Dasatinib, originally developed as a cancer drug, and quercetin, a natural plant flavonoid found in many fruits and vegetables, together form the first senolytic pair studied in human clinical trials. Their combined use offers a novel approach to not just slowing aging but improving function and quality of life during aging—something that has captured the attention of researchers and longevity enthusiasts alike.
The Science Behind Dasatinib and Quercetin
To appreciate the excitement around this combination, it helps to understand the biology involved. Senescent cells resist apoptosis—the programmed cell death that normally clears damaged cells—by activating a network of survival pathways often referred to as the senescent cell anti-apoptotic pathways (SCAPs). Targeting these SCAPs is the key to selectively killing senescent cells without harming healthy cells.
Dasatinib is a tyrosine kinase inhibitor approved for certain leukemias. It interrupts signaling pathways that some senescent cells depend on for survival, particularly in fat and connective tissues. Quercetin, on the other hand, inhibits different survival pathways, including PI3K and serpins, effective against senescent endothelial cells and other types. By combining these two agents, researchers can target a broader range of senescent cells than either can alone.
In vitro studies first demonstrated that dasatinib and quercetin (often abbreviated as D+Q) could reduce senescent cell burden effectively. From there, the leap into animal models showed improvements in physical function, cardiac health, and markers of inflammation with D+Q treatment.
Key Research Findings in Humans
The hallmark study that launched dasatinib and quercetin into the spotlight for human senolytic use came from Justice et al. (2019), published in EBioMedicine. This pilot clinical trial enrolled 14 patients with idiopathic pulmonary fibrosis (IPF), a lung disease heavily linked to senescent cell accumulation. Participants were given a short course of D+Q—dasatinib (100 mg/day) and quercetin (1250 mg/day) over three consecutive days each week for three weeks.
“The treatment was well tolerated and associated with improved physical function tests, suggesting that senolytics might alleviate disease symptoms related to cellular senescence.”[1]
Building on that, Hickson et al. (2019) conducted a randomized, placebo-controlled trial in older adults with diabetic kidney disease, published in EBioMedicine. They observed that short-term D+Q dosing reduced senescent cell markers in adipose tissue and decreased circulating inflammatory cytokines. Notably, measures of physical function like walking speed improved following treatment.
These early human trials are significant because they show feasibility and preliminary efficacy for senolytic therapy in real-world age-related conditions. However, more extensive studies are needed to confirm long-term benefits and safety.
How Does Dasatinib and Quercetin Compare to Other Senolytic Approaches?
| Aspect | Dasatinib + Quercetin (D+Q) | Navitoclax (ABT-263) | Fisetin | Others (e.g., FOXO4-DRI peptide) |
|---|---|---|---|---|
| Type | Tyrosine kinase inhibitor + flavonoid | BCL-2 family inhibitor | Natural flavonoid | Peptide-based senolytic |
| Target Senescent Cells | Broad range (fat, endothelium, connective tissue) | Primarily hematopoietic lineage, some tissue senescent cells | Various tissues, overlapping with quercetin | Fibroblasts and certain senescent cell types |
| Human Clinical Trials | Yes (IPF, diabetic kidney disease) | Limited, mainly oncology use, toxicity challenges | Early-stage human trials ongoing | Preclinical, early-stage research |
| Toxicity / Side Effects | Generally well-tolerated in short courses, but dasatinib has known risks | Significant thrombocytopenia and other toxicities | Generally safe, low toxicity | Unclear, preclinical data only |
| Dosing Frequency | Intermittent, short bursts (e.g., 3 days/week for 3 weeks) | Continuous, limited by toxicity | Varies, often intermittent | Experimental, not standardized |
Practical Takeaways and Dosage Considerations
From what the research shows, the intermittent dosing of dasatinib and quercetin appears key. Because senolytics selectively kill senescent cells without affecting healthy cells, continuous dosing isn’t necessary and may increase side effects unnecessarily. The clinical trials usually employ short courses—such as three consecutive days of dasatinib 100 mg plus quercetin 1250 mg daily, repeated weekly for several weeks.
Quercetin is widely available as a supplement and has a strong safety record. Dasatinib, however, is a prescription medication with potential serious side effects, including cytopenias, fluid retention, and cardiac effects, so it should only be taken under medical supervision. Self-medicating with dasatinib is strongly discouraged.
For those interested in the senolytic properties of quercetin alone or with related compounds like fisetin, supplementation is common, but evidence in humans is still emerging. Most experts recommend consulting healthcare providers before starting any new regimen targeting senescence.
Another point worth mentioning: lifestyle factors such as regular exercise, calorie moderation, and avoiding chronic inflammation remain the cornerstone of healthy aging. Senolytics like D+Q are promising adjuncts but not magic bullets.
Frequently Asked Questions
1. What exactly are senolytics, and how do they work?
Senolytics are compounds that selectively induce death of senescent cells—cells that have stopped dividing and contribute to aging and disease by secreting harmful factors. By targeting survival pathways unique to these cells, senolytics clear them out, potentially reducing inflammation and tissue dysfunction.
2. Why combine dasatinib and quercetin instead of using one alone?
Different senescent cells rely on different survival pathways. Dasatinib targets some types of senescent cells, such as those in fat and connective tissue, while quercetin targets others like endothelial cells. Together, they cover a wider range of senescent cell types, increasing efficacy.
3. Are there risks or side effects associated with dasatinib and quercetin treatment?
Yes. Dasatinib, as a cancer drug, can cause side effects like low blood counts, fluid retention, and heart issues, so its use must be carefully monitored by a doctor. Quercetin is generally safe but can interact with some medications. The short dosing regimens used in senolytic trials seem to minimize risks compared to chronic dosing.
4. Is dasatinib and quercetin therapy available outside clinical trials?
Dasatinib is prescription-only and approved for certain leukemias, not as a senolytic. While quercetin supplements are widely accessible, the combination as a senolytic therapy is currently experimental and mostly limited to clinical research settings. Anyone interested should consult a healthcare professional before pursuing such treatments.
5. How soon can we expect senolytic therapies like D+Q to become mainstream?
While the early results are promising, senolytic therapies are still in the early phases of clinical research. Larger, longer-term studies are needed to confirm benefits, optimal dosing, and safety. It may take several years before these treatments become widely available outside of trials.
6. Can lifestyle changes reduce senescent cell burden?
Absolutely. Regular exercise, a balanced diet rich in antioxidants, avoiding smoking, and managing chronic inflammation can reduce the formation and accumulation of senescent cells. Senolytics are likely to complement, not replace, healthy living habits.
References
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-in-Human, Open-Label, Pilot Study. EBioMedicine. 2019;40:554-563. doi:10.1016/j.ebiom.2018.12.052
- Hickson LJ, Langhi Prata LJ, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. doi:10.1016/j.ebiom.2019.08.069
- Xu M, Palmer AK, Ding H, et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife. 2015;4:e12997. doi:10.7554/eLife.12997
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. EBioMedicine. 2015; 21: 12-20. doi:10.1016/j.ebiom.2016.03.029
- Roos CM, Zhang B, Palmer AK, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Age (Dordr). 2016;38(2):49. doi:10.1007/s11357-016-9909-5
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. doi:10.1016/j.ebiom.2018.09.015
- Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424-1435. doi:10.1038/nm.4000
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any new treatment or supplement, especially prescription medications such as dasatinib. Senolytic therapies are experimental and should only be used under clinical supervision.